Aprea Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aprea Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.60M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($12.96M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($14.29M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($112.66M) | Mar 26, 2024 |
| FY2023 | Dec 31, 2021 | ($37.13M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | ($53.48M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($28.06M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | ($15.53M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | ($15.19M) | Mar 27, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.23M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($14.32M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($15.47M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($113.39M) | Mar 26, 2024 |
| FY2023 | Dec 31, 2021 | ($37.45M) | Mar 26, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $23.90M | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | $37.88M | Mar 15, 2022 |
| FY2021 | Dec 31, 2019 | $20.95M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $14.19M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $13.39M | Mar 27, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.89M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($13.56M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($12.18M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($25.01M) | Mar 26, 2024 |
| FY2023 | Dec 31, 2021 | ($37.69M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | ($41.80M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($26.71M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | ($15.25M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | ($14.00M) | Mar 27, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $15.5K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $93.1K | Mar 25, 2025 |
| FY2022 | Dec 31, 2020 | $25.7K | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $30.9K | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $3.7K | Mar 16, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.93M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $23.98M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $22.65M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $30.16M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $56.82M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $92.81M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $133.61M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $66.02M | Mar 27, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.20M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $7.32M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $15.41M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $9.36M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $4.87M | Mar 27, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.44M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $19.31M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $16.95M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $25.64M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $49.51M | Mar 26, 2024 |
| FY2023 | Dec 31, 2020 | $77.40M | Mar 26, 2024 |
| FY2022 | Dec 31, 2019 | $124.24M | Mar 30, 2023 |
| FY2021 | Dec 31, 2018 | ($51.44M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2017 | ($35.77M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2016 | ($21.47M) | Mar 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($333.64M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($321.04M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($308.08M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($293.80M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($181.13M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($144.01M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($90.53M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($62.47M) | Mar 27, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.60M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $22.85M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $21.61M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $28.79M | Mar 26, 2024 |
| FY2023 | Dec 31, 2021 | $53.08M | Mar 26, 2024 |
| FY2021 | Dec 31, 2020 | $89.02M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $130.09M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $65.68M | Mar 27, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (67) | Mar 26, 2024 |
| FY2023 | Dec 31, 2021 | (34) | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | (50) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | (4) | Mar 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (67) | Mar 26, 2024 |
| FY2023 | Dec 31, 2021 | (34) | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | (50) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | (4) | Mar 15, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.19M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 5.48M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 3.74M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 2.66M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 1.09M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 21.19M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 21.02M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 1.16M | Mar 27, 2020 |